Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03455907
NCT03455907CompletedNot Applicable

Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer

University Hospital, Lille2 sites in 1 country71 target enrollmentStarted: January 3, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
71
Locations
2
Primary Endpoint
Frequency of arthralgia
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers.

The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy
  • •Male or female (aged ≥18 years old)
  • •Performance Status (PS) between 0 and 2
  • •Expected life> 3 months
  • •Ability to answer a self-questionnaire
  • •Obtaining the non-opposition of patient participation

Exclusion Criteria

  • •Pregnant or lactating woman
  • •Rapid evolution of neoplastic pathology
  • •Major cognitive disorders that do not allow filling of the self-questionnaire
  • •Impossibility to submit to medical monitoring for social, psychological or geographical reasons
  • •Patients under guardianship or curatorship

Arms & Interventions

Patients

patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab

Outcomes

Primary Outcomes

Frequency of arthralgia

Time Frame: At 6 months

Frequency of joint manifestations of any grade according to the CTCAE (Common Terminology Criteria for Adverse Events) scale version 4.0 observed between the start of bevacizumab treatment and 6 months of treatment.

Secondary Outcomes

  • correlation between global cancer response and occurrence of arthralgia(baseline, at 3 months, at 6 months)
  • auto questionnaire specific to the study(Baseline at 3 months, at 6 months)

Investigators

Sponsor
University Hospital, Lille
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed
Not Applicable
Association Between Clinical Signs and MRI Findings of the Lumbar Facet JointsLow Back PainFacet Joint Pain
NCT01628939Christoph Maier, Prof. Dr.150
Active, not recruiting
Phase 1
Joint pain personalised treatment assessment to investigate the acceptability of modified release oxycontin for managing chronic pain in patients with osteoarthritis of the hip - Joint Pain PTAHip Osteoarthritis
EUCTR2005-004527-19-GBMRC Health Services Research Collaboration20
Unknown
Not Applicable
Human Physiology and Self-Reported Pain ScoreCancer Pain
NCT04053608Taichung Veterans General Hospital20
Completed
Not Applicable
Gait Modification Treatments for Knee PathologyKnee InjuriesKnee Osteoarthritis
NCT03116230Stanford University38
Recruiting
Phase 1
Clinical observation on the treatment of joint swelling and pain due to the Fengtabuzu syndrome of RA by Dai medicine LongmengshahousaRA
ITMCTR2100004644Yunnan Hospital of Traditional Chinese Medicine